An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Trial Status: complete
This Phase 3 clinical study compares the efficacy and safety of elacestrant to the
standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and
men with breast cancer whose disease has advanced on at least one endocrine therapy
including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor
(AI).
Inclusion Criteria
Participants with proven diagnosis of adenocarcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy.
Participants must be appropriate candidates for endocrine monotherapy
Participants must have measurable disease or bone only disease with evaluable lesions
Female or male participants age ≥ 18 years; female participants must be postmenopausal women, and male participants must not allow pregnancy with their sperm (abstain, do not donate sperm, et cetera).
Participants must have ER+ and HER2- tumor status
Participants must have previously received at least one and no more than two lines of endocrine therapy for advanced/metastatic breast cancer and meet additional previous treatment criteria.
Participants must have received prior treatment with a CDK4/6 inhibitor in combination with either fulvestrant or an aromatase inhibitor (AI) for advanced/metastatic breast cancer (mBC).
Participants may have received no more than one line of chemotherapy in the advanced/metastatic setting. Critical
Exclusion Criteria
Prior treatment with elacestrant or other investigational selective estrogen receptor degrader (SERD) or ER antagonist (D-0502, GDC-0810, GDC-0927, GDC-9545, G1T-48, LSZ102, AZD9496, SAR439859, ZN-c5, H3B-6545, bazedoxifene, lasofoxifene).
Prior anticancer or investigational drug treatment within the following windows:
Fulvestrant treatment < 42 days before first dose of study drug
Any endocrine therapy < 14 days before first dose of study drug
Chemotherapy < 21 days before first dose of study drug
Any investigational anti-cancer drug therapy < 28 days or five half-lives (whichever is shorter) before the first dose of study drug. Enrollment of participants whose most recent therapy was an investigational agent should be discussed with the Sponsor
Bisphosphonates or RANKL inhibitors initiated or dose changed < 3 months prior to first dose of study drug
Presence of symptomatic visceral disease as defined in protocol.
Additional locations may be listed on ClinicalTrials.gov for NCT03778931.
Locations matching your search criteria
United States
New Mexico
Albuquerque
University of New Mexico Cancer Center
Status: Active
Name Not Available
Pennsylvania
Philadelphia
Thomas Jefferson University Hospital
Status: Approved
Name Not Available
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Status: Active
Name Not Available
This is an international, multicenter, randomized, open-label, active-controlled,
event-driven, Phase 3 clinical study comparing the efficacy and safety of elacestrant to
the SoC options of fulvestrant or an aromatase inhibitor (AI) in postmenopausal women and
in men with advanced or metastatic ER+/HER2- breast cancer, either in participants with
tumors that harbor mutations in the ligand binding domain (LBD) of the estrogen receptor
1 (ESR1) gene (ESR1-mut participants) or in all participants regardless of ESR1 status
(ESR1-mut and ESR1 wild type [ESR1-wt]) and whose disease has relapsed or progressed on
at least one and no more than two prior lines of endocrine therapy (with documented
progression), which must have included prior CDK4/6 inhibitor therapy in combination with
fulvestrant or an aromatase inhibitor (AI) and for whom hormonal monotherapy with one of
the SoC drugs (fulvestrant, anastrozole, letrozole, exemestane) is an appropriate
